NCT04442048View on ClinicalTrials.gov

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

May 7, 2024

Study Completion Date

December 31, 2025

Conditions
CancerCovid-19
Interventions
BIOLOGICAL

IMM-101

Three doses of IMM-101 on days 0, 14, and 45.

OTHER

Observation

No active treatment. Observation only

Trial Locations (8)

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H4A 3J1

The Research Institute of the McGill University, Montreal

J1H 5N4

CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke

Sponsors
All Listed Sponsors
collaborator

Immodulon Therapeutics Ltd

INDUSTRY

collaborator

BioCan Rx

UNKNOWN

collaborator

Canadian Cancer Society (CCS)

OTHER

collaborator

ATGen Canada Inc

INDUSTRY

collaborator

Canadian Centre for Applied Research in Cancer Control (ARCC)

UNKNOWN

collaborator

Ontario Institute for Cancer Research

OTHER

lead

Canadian Cancer Trials Group

NETWORK